中国中医药研究促进会书记指出："玄黄模型将AI的'算力'转化为中医传承创新的'生产力'，为破解中医 药标准化难题提供了新范式。" 论坛期间，北京怀柔医院、怀柔区中医医院、怀柔区妇幼保健院、雁栖医院与观薇智能签署战略协议。 观薇智能与琉璃妙科技的智能医养AI场景共建签约、观薇智能与天津方面的智能AI场景应用共建签 约，各方合作协议的签署，标志着怀柔科学城在"人工智能+大健康"领域生态共建迈出了坚实且关键的 步伐。未来，各方将在智能AI场景应用领域开展全方位合作，整合京津冀地区的产业资源、技术力量 和市场需求，共同探索AI在大健康领域的创新应用模式，提升区域整体的产业竞争力。 据了解，怀柔区科技创新企业观薇智能科技（北京）有限公司开发的"玄黄大模型及算法"，于4月10日 获得国家网信办备案，是怀柔区第一个正式备案的人工智能模型。 怀柔区经信局副局长、区人工智能专班主任康卫表示："玄黄大模型的发布，是怀柔科学城落实国家新 一代人工智能发展战略的关键一步，将加速构建'科学+城'的融合创新生态。" 作为怀柔科学城首个自主培育并完成备案的AI大模型，"玄黄"由观薇智能联合智谱AI、中国中医科学院 中医药信息研究所、上海中 ...

Core Viewpoint - The steady growth of the Chinese economy and its commitment to medical innovation are crucial drivers shaping the future of the global industry [1][2] Group 1: Company Overview - Wan Yi Te is a significant organ therapy company with a product line that includes peritoneal dialysis, hemodialysis, and critical care treatment [1] - Since entering the Chinese market in 1989, Wan Yi Te has established a complete industrial chain covering R&D, manufacturing, sales, and services [1] - The company has its China headquarters in Shanghai, with a world-class R&D center and production bases in Suzhou, Guangzhou, and Tianjin [1] Group 2: Market Insights - The Chinese market is a vital pillar of Wan Yi Te's global strategy, being the second-largest medical device market in the world [2] - There is a significant demand for high-quality medical health services and personalized treatment options among the Chinese population [2] - Favorable policies in digital healthcare, home treatment, and chronic disease management align with Wan Yi Te's mission to enhance patient care and treatment efficiency [2] Group 3: Future Directions - Wan Yi Te aims to seek more collaboration opportunities in China, believing that strong local partnerships can leverage advantages and embrace changes in the medical field [3]